ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2018
Price : $35 *
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 31 Aug 2018 Biomarkers information updated
- 29 May 2018 Status changed from recruiting to suspended.
- 05 Jun 2017 Planned End Date changed from 1 Oct 2021 to 29 Oct 2021.